|Table of Contents|

Comparative analysis of the prognostic impact of subtotal gastrectomy and total gastrectomy on patients with gastric cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 09
Page:
1677-1682
Research Field:
Publishing date:

Info

Title:
Comparative analysis of the prognostic impact of subtotal gastrectomy and total gastrectomy on patients with gastric cancer
Author(s):
ZHENG Cheng1; 2; MA Ting2; ZHANG Yue1; JING Xiaoying2; LI Xinghui1; ZHANG Hong1; DING Wenqing1; YANG Wenjun3; 4
1.School of Public Health and Management,Ningxia Medical University,Ningxia Yinchuan 750004,China;2.School of Basic Medicine,Ningxia Medical University,Ningxia Yinchuan 750004,China;3.The First Affiliated Hospital,Hainan Medical University,Hainan Haikou 571199,China；4.Cancer Institute,the General Hospital of Ningxia Medical University,Ningxia Yinchuan 750004,China.
Keywords:
gastric cancer; subtotal gastrectomy; total gastrectomy; tumor location; prognosis
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2023.09.017
Abstract:
Objective:To compare the survival effect of subtotal gastrectomy (SG) and total gastrectomy (TG) in gastric cancer patients.Methods:The general demographic data,clinicopathological data,and prognosis information of 1 903 patients with stage II/III gastric cancer who were admitted to the General Hospital of Ningxia Medical University from December 2009 to September 2017 were retrospectively collected.1 020 cases (53.6%) in the SG group,883 cases (46.4%) in the TG group,using univariate and multivariate analysis to analyze the survival difference and prognostic factors of the two groups of patients.Results:Compared with the TG group,the SG group had a higher overall survival rate (67.3% vs 49.0%,P＜0.001).The results of univariate and multivariate analysis all supported that age,clinical stage,tumor location,chemotherapy,etc.were independent prognostic factors for patients with gastric cancer(P＜0.05).Further stratified by tumor location and stage,the overall survival rate of patients with tumors located in the upper segment was lower than that of patients in the middle and lower segments (58.3% vs 66.6%,62.6%,P＜0.05).The long-term survival rates of patients with tumors located in the upper and middle segments receiving SG and TG were comparable.The long-term survival rate of the tumor located in the lower segment of the TG group was significantly higher than that of the SG group (30.6% vs 17.1%,29.4% vs 3.7%,P＜0.05).Conclusion:Compared with total gastrectomy,distal subtotal gastrectomy can improve the short-term survival rate of patients with stage II/III gastric cancer,regardless of the location of the tumor in the upper,middle and lower segments,for patients with poorly differentiated and late stage of distal gastric cancer,total gastrectomy can be performed routinely when circumstances permit.

References:

［1］ SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］ JAPANESE GASTRIC CANCER A.Japanese gastric cancer treatment guidelines 2018 (5th edition)［J］.Gastric Cancer,2021,24(1):1-21.
［3］ KATAI H,MIZUSAWA J,KATAYAMA H,et al.Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage Ia/Ib gastric cancer:Japan Clinical Oncology Group Study JCOG0912［J］.Gastric Cancer,2017,20(4):699-708.
［4］ JIANG Y,LI T,LIANG X,et al.Association of adjuvant chemotherapy with survival in patients with stage II or III gastric cancer［J］.JAMA Surg,2017,152(7):e171087.
［5］ JOSHI SS,BADGWELL BD.Current treatment and recent progress in gastric cancer［J］.CA Cancer J Clin,2021,71(3):264-279.
［6］ QI J,ZHANG P,WANG Y,et al.Does total gastrectomy provide better outcomes than distal subtotal gastrectomy for distal gastric cancer? A systematic review and Meta-analysis［J］.PLoS One,2016,11(10):e0165179.
［7］ LEE JH,KIM YI.Which is the optimal extent of resection in middle third gastric cancer between total gastrectomy and subtotal gastrectomy［J］.J Gastric Cancer,2010,10(4):226-233.
［8］ PARK S,CHUNG HY,LEE SS,et al.Serial comparisons of quality of life after distal subtotal or total gastrectomy:what are the rational approaches for quality of life management［J］.J Gastric Cancer,2014,14(1):32-38.
［9］ NOH SH,PARK SR,YANG HK,et al.Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):5-year follow-up of an open-label,randomised phase 3 trial［J］.The Lancet Oncology,2014,15(12):1389-1396.
［10］ 张祚聪.远端胃癌根治术后三种常见消化道重建方式的临床对比分析［D］.长春：吉林大学,2017. ZHANG JC.Clinical comparison analysis of three common GI reconstruction modalities after radical surgery for distal gastric cancer［D］.Changchun:Jilin University,2017.
［11］ JI X,YAN Y,BU ZD,et al.The optimal extent of gastrectomy for middle-third gastric cancer:distal subtotal gastrectomy is superior to total gastrectomy in short-term effect without sacrificing long-term survival［J］.BMC Cancer,2017,17(1):345.
［12］ ROBERTSON CS,CHUNG SC,WOODS SD,et al.A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer［J］.Ann Surg,1994,220(2):176-182.
［13］ LIU Z,FENG F,GUO M,et al.Distal gastrectomy versus total gastrectomy for distal gastric cancer［J］.Medicine (Baltimore),2017,96(5):e6003.
［14］ MOCAN L,TOMUS C,BARTOS D,et al.Long term outcome following surgical treatment for distal gastric cancer［J］.J Gastrointestin Liver Dis,2013,22(1):53-58.
［15］ KANG WM,MENG QB,YU JC,et al.Factors associated with early recurrence after curative surgery for gastric cancer［J］.World J Gastroenterol,2015,21(19):5934-5940.
［16］ DENG J,LIANG H,WANG D,et al.Investigation of the recurrence patterns of gastric cancer following a curative resection［J］.Surgery Today,2011,41(2):210-215.
［17］ ALNOOR M,BOYS JA,WORRELL SG,et al.Timing and pattern of recurrence after gastrectomy for adenocarcinoma［J］.The American Surgeon,2015,81(10):1057.
［18］ SPOLVERATO G,EJAZ A,KIM Y,et al.Rates and patterns of recurrence after curative intent resection for gastric cancer:A United States multi-institutional analysis［J］.Journal of the American College of Surgeons,2014,219(4):664-675.
［19］ YAGO A,HARUTA S,UENO M,et al.Correction to:Adequate period of surveillance in each stage for curatively resected gastric cancer:analyzing the time and rates of recurrence［J］.Gastric Cancer,2021,24(3):762-763.
［20］ MAZZEI MA,DI GIACOMO L,BAGNACCI G,et al.Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer-a multicenter study of GIRCG (Italian Research Group for Gastric Cancer)［J］. Quant Imaging Med Surg,2021,11(6):2376-2387.
［21］ LI Z,BAI B,XIE F,et al.Distal versus total gastrectomy for middle and lower-third gastric cancer:A systematic review and meta-analysis［J］.Int J Surg,2018,53:163-170.
［22］ 杨明.全胃切除术及远端胃切除术后生存质量影响因素的分析［D］.苏州：苏州大学,2019. YANG M.Analysis of factors influencing quality of survival after total gastrectomy and distal gastrectomy［D］.Suzhou:Soochow University,2019.
［23］ 梁铁柱,闫文,朱一宁.胃癌患者不同部位肿瘤手术治疗的术式选择［J］.当代医学,2015,21(02):77-78. LIANG TZ,YAN W,ZHU YN.Surgical options for the surgical treatment of tumors at different sites in patients with gastric cancer［J］.Contemporary Medicine,2015,21(02):77-78.
［24］ JU T,RIVAS L,KURLAND K,et al.National trends in total vs subtotal gastrectomy for middle and distal third gastric cancer［J］.Am J Surg,2020,219(4):691-695.
［25］ PARKS H,LIMD H,SOHNT S,et al.A randomized phase III trial comparing adjuvant single-agent S1,S-1 with oxaliplatin,and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection:the ARTIST 2 trial［J］.Ann Oncol,2021,32(3):368-374.
［26］ XING X,SHI J,JIA Y,et al.Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis［J］.J Immunother Cancer,2022,10(3):e003984.
［27］ BANG Y,KIM Y,YANG H,et al.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):a phase 3 open-label,randomised controlled trial［J］.Lancet (London,England),2018,379(9813):315-321.
［28］ KAKEJI Y,YOSHIDA K,KODERA Y,et al.Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer:JACCRO GC-07［J］.Gastric Cancer,2022,25(1):188-196.

Memo

Memo:
National Natural Science Foundation of China(No.82160535，81760525）；国家自然科学基金项目（编号：82160535，81760525）；宁夏自然科学基金项目（编号：2022A1043，2022AAC03544）
Last Update: 2023-03-30